Literature DB >> 2703514

The validity of survivorship analysis in total joint arthroplasty.

F Dorey1, H C Amstutz.   

Abstract

The use of survivorship analysis requires an assumption that patients who are lost to follow-up are no more or less likely to be at risk of failure of an operation or a procedure than are patients who are still being followed. This is a major assumption in long-term orthopaedic studies, in which a high percentage of patients are usually lost to follow-up. We compared the survivorship curve for the first 100 Tharies replacements done at our institution (which were completed by September 1977), using data that were collected in the standard way up to 1985, through a letter requesting a follow-up visit, with the curve for the same patients that was based on almost complete follow-up data that were gathered by telephone from 1985 on. The similarity of the two curves suggested that the assumptions that are necessary for the validity of survivorship analysis are reasonable, even in the orthopaedic setting, in which many patients are lost to follow-up. The usefulness of the survivorship curve for prediction was also evaluated by comparing the curve based on the first forty-six of the 100 Tharies replacements (before 1977) with the curve based on the last fifty-four such operations (from January 1977 to September 1977). The results of these two comparisons suggest that survivorship analysis is a valid technique to use in the long-term evaluation of patients who have had a joint replacement.

Entities:  

Mesh:

Year:  1989        PMID: 2703514

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  17 in total

1.  The Ring total knee replacement--a comparison of survivorship.

Authors:  M J Curtis; J M Bland; P A Ring
Journal:  J R Soc Med       Date:  1992-04       Impact factor: 5.344

2.  Aseptic loosening of straight- and curved-stem Müller femoral prostheses.

Authors:  M Krismer; M Klar; T Klestil; B Frischhut
Journal:  Arch Orthop Trauma Surg       Date:  1991       Impact factor: 3.067

3.  Uncoated polyethylene RM acetabular component versus Müller cemented acetabular component. A 4- to 8-year follow-up study.

Authors:  M Krismer; M Fischer; T Klestil; B Frischhut
Journal:  Arch Orthop Trauma Surg       Date:  1991       Impact factor: 3.067

4.  Cementing the metaphyseal stem in metal-on-metal resurfacing: when and why.

Authors:  Harlan C Amstutz; Michel J Le Duff
Journal:  Clin Orthop Relat Res       Date:  2008-10-30       Impact factor: 4.176

Review 5.  Correlation between patient age at total hip replacement surgery and lifeexpectancy.

Authors:  Carlos Roberto Schwartsmann; Leandro de Freitas Spinelli; Leonardo Carbonera Boschin; Anthony Kerbes Yépez; Marcus Vinicius Crestani; Marcelo Faria Silva
Journal:  Acta Ortop Bras       Date:  2015 Nov-Dec       Impact factor: 0.513

6.  Long-term results of Charnley low friction arthroplasty in patients younger than 40.

Authors:  B Chamberiin; L Kerboull; M Kerboull
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-10

7.  How are those "lost to follow-up" patients really doing? A compliance comparison in arthroplasty patients.

Authors:  Jung Keun Choi; Jeffrey A Geller; David A Patrick; Wenbao Wang; William Macaulay
Journal:  World J Orthop       Date:  2015-01-18

8.  Factors affecting patient compliance in the acute setting: an analysis of 20,000 imaging reports.

Authors:  Waqas Shuaib; Arvind Vijayasarathi; Jamlik-Omari Johnson; Ninad Salastekar; Qing He; Kiran Kumar Maddu; Faisal Khosa
Journal:  Emerg Radiol       Date:  2014-03-11

9.  Lost to follow-up: reasons and outcomes following tibial plateau fractures.

Authors:  Martin F Hoffmann; Debra L Sietsema; Clifford B Jones
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-07-21

10.  Periprosthetic fractures in total hip arthroplasty: an epidemiologic study.

Authors:  Roope Sarvilinna; Heini S A Huhtala; Timo J S Puolakka; Juha K Nevalainen; K Jorma J Pajamäki
Journal:  Int Orthop       Date:  2003-07-30       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.